Drugs / Dexrazoxane
Dexrazoxane
also known as
dexrazoxane hydrochloride · ADR-529 · ADR-529 HYDROCHLORIDE · Cardioxan · Cardioxane · Cardioxane (Dexrazoxane) · Dexrazoxane for Injection · Dexrazoxane hcl · +10 more
Small molecule targets TOP2B
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | TOTECT | — | 2020-11-02 | fda.gov ↗ |
| Approved | EU (EMA) | Savene | — | 2006-07-27 | europa.eu ↗ |
| Label expansion | US (FDA) | ZINECARD | — | 2002-10-31 | fda.gov ↗ |
| Approved | US (FDA) | ZINECARD | — | 1995-05-26 | fda.gov ↗ |
Trials 23 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 32 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT05858710 Background | Apr 2023 → Jan 2025 | soft tissue sarcoma | Thermosome GmbH | Completed | No outcome recorded |
| Phase 1 | NCT05292664 Background | Mar 2023 → Jul 2028 expected | acute leukemia of ambiguous lineage, acute lymphoblastic leukemia, lymphoblastic lymphoma, myelodysplastic syndrome +1 | Andrew E. Place, MD | Recruiting | No outcome recorded |
| Phase 1 | NCT01606878 Background | Apr 2013 → Dec 2018 | anaplastic large cell lymphoma, childhood malignant neoplasm, neuroblastoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT01523977 Background | Nov 2011 → Jan 2017 | acute lymphoblastic leukemia | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT01258634 Background | Jul 2010 → Nov 2011 | osteosarcoma, respiratory system cancer | University of Chicago | Terminated | No outcome recorded |
| Phase 1 | NCT00933985 Background | Jun 2009 → Apr 2013 | Burkitt lymphoma, Hodgkins lymphoma, acute undifferentiated leukemia, anaplastic large cell lymphoma +15 | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00928200 Background | Apr 2009 → Jun 2010 | acute lymphoblastic leukemia | Therapeutic Advances in Childhood Leukemia Consortium | Terminated | No outcome recorded |
| Phase 1 | NCT00742924 Background | Aug 2008 → Apr 2012 | sarcoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00098839 Background | Feb 2005 → Apr 2011 | childhood acute lymphoblastic leukemia | Children's Oncology Group | Completed | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT06262438 Background | Feb 2024 → Jun 2028 expected | childhood acute myeloid leukemia | Princess Maxima Center for Pediatric Oncology | Recruiting | No outcome recorded |
| Phase 2 | NCT03698227 Background | Nov 2018 → Jun 2020 | soft tissue sarcoma | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Terminated | No outcome recorded |
| Phase 2 | NCT03164057 Background | Jun 2017 → Sep 2025 overdue | acute myeloid leukemia, myelodysplastic syndrome | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01871766 Background | Dec 2013 → Dec 2026 expected | rhabdomyosarcoma | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01864109 Background | May 2013 → May 2027 expected | Ewing sarcoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01696669 Background | Mar 2010 → Dec 2017 | Ewing sarcoma | Spanish Group for Research in Sarcomas | Completed | No outcome recorded |
| Phase 2 | NCT00077285 Background | Oct 2003 → Oct 2027 expected | sarcoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00084838 Background | Feb 2003 → Feb 2008 | central nervous system cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00544778 Background | Aug 2001 → Nov 2011 | sarcoma | City of Hope Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT00019864 Background | Mar 2000 → Dec 2006 | chemotherapy-induced toxicity, sarcoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00038142 Background | Nov 1997 → Mar 2016 | Ewing sarcoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 310 trials | ||||||
| Phase 3 | NCT06647953 Background | Mar 2025 → Mar 2029 expected | pleuropulmonary blastoma | Children's Oncology Group | Recruiting | No outcome recorded |
| Phase 3 | NCT04478292 Background | Mar 2021 → Mar 2027 expected | hepatoblastoma | Shanghai Children's Medical Center | Recruiting | No outcome recorded |
| Phase 3 | NCT03126916 Background | May 2018 → Sep 2030 expected | neuroblastoma, nodular ganglioneuroblastoma | Children's Oncology Group | Recruiting | No outcome recorded |
| Phase 3 | NCT03007147 Background | Aug 2017 → Sep 2027 expected | B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, mixed phenotype acute leukemia | Children's Oncology Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03020030 Background | Mar 2017 → Nov 2026 expected | childhood acute lymphoblastic leukemia | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01231906 Background | Nov 2010 → Mar 2020 | extraskeletal Ewing sarcoma, peripheral primitive neuroectodermal tumor of bone, peripheral primitive neuroectodermal tumor of soft tissues | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00980460 Background | Sep 2009 → Jun 2020 | hepatoblastoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00334867 Background | Dec 2005 → Jan 2006 | sarcoma | Children's Oncology Group | Withdrawn | No outcome recorded |
| Phase 3 | NCT00400946 Background | Apr 2005 → Aug 2014 | leukemia, poisoning | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 3 | NCT01230983 Comparator | Jun 1996 → Sep 2001 | acute leukemia, chemotherapy-induced toxicity, lymphoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT00673179 Background | May 2008 → Nov 2010 | osteosarcoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| — | NCT00410488 Comparator | Dec 2006 → Jun 2011 | sarcoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 23 cited values
Every value below carries the sentence it was read from. 58 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dexrazoxane | “* Dexrazoxane: administered at a dose of 10:1, before doxorubicin only in adults.” NCT01696669 ↗43“(Dexrazoxane : 300 mg/m2/dose Day 1 and 2, where is available)” NCT04478292 ↗ “Dexrazoxane 900 mg/m\^2 IV (30 minutes prior to doxorubicin)” NCT00038142 ↗ |
| Known as | ADR-529 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001335 ↗ |
| Known as | ADR-529 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738 ↗ |
| Known as | Cardioxan | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738 ↗ |
| Known as | Cardioxane | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738 ↗ |
| Known as | Cardioxane (Dexrazoxane) | “Cardioxane® (Dexrazoxane)” NCT01627938 ↗ |
| Known as | Dexrazoxane for Injection | “Dexrazoxane for Injection” NCT00955890 ↗ |
| Known as | Dexrazoxane hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738 ↗ |
| Known as | dexrazoxane hydrochloride | “doxorubicin hydrochloride and dexrazoxane hydrochloride IV continuously over 96 hours.” NCT00544778 ↗14“dexrazoxane hydrochloride IV continuously over 96 hours beginning on day 1” NCT00550901 ↗ “Drug: dexrazoxane hydrochloride” NCT00077285 ↗ “Drug: dexrazoxane hydrochloride” NCT00002827 ↗ “Drug: Dexrazoxane hydrochloride” NCT00955890 ↗ “Drug: dexrazoxane hydrochloride” NCT00003937 ↗ |
| Known as | dexrazoxane injection | “dexrazoxane injection” NCT00955890 ↗ |
| Known as | Dexrazoxano | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738 ↗ |
| Known as | ICRF-187 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738 ↗ |
| Known as | ICRF-187 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738 ↗ |
| Known as | KDX-0811 | “A Phase I/II Study of KDX-0811(Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents” NCT01596088 ↗ |
| Known as | NSC-169780 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738 ↗ |
| Known as | Savene | “BACKGROUND: The purpose of this study was to assess the efficacy and tolerability of i.v. dexrazoxane [Savene (EU), Totect (US)] as acute antidote in biopsy-verified...” PMID 17185744 ↗ Dec 2006 |
| Known as | Topotect | “A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines” NCT00548704 ↗ |
| Known as | Totect | “BACKGROUND: The purpose of this study was to assess the efficacy and tolerability of i.v. dexrazoxane [Savene (EU), Totect (US)] as acute antidote in biopsy-verified...” PMID 17185744 ↗ Dec 2006 |
| Known as | Zinecard | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00410488 ↗ |
| Action | Inhibit | “Topoisomerase II Inhibitor” NCT07654426 ↗ |
| Modality | Small molecule | — CHEMBL1738 ↗ |
| Route | Intravenous | “Given IV” NCT00002827 ↗ |
| Target | TOP2B | “dexrazoxane is also a catalytic inhibitor of topoisomerase 2b (Top2b), a key mediator of doxorubicin toxicity.” PMID 40317097 ↗ May 2025 |